quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:10:26·87d
INSIDERFiling
Sangamo Therapeutics Inc. logo

PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 102,950 shares, decreasing direct ownership by 5% to 1,946,584 units (SEC Form 4)

SGMO· Sangamo Therapeutics Inc.
Health Care
Original source

Companies

  • SGMO
    Sangamo Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Nov 7UpdateBarclays$1.00
  • Dec 13UpdateTruist$7.00
  • Dec 10UpdateH.C. Wainwright$10.00
  • Nov 3UpdateRBC Capital Mkts$2.00
  • Apr 28UpdateBofA Securities$1.50
  • Feb 27UpdateWedbush$16.00

Related

  • INSIDER10h
    Head of Research & Technology Davis Gregory D sold $17,694 worth of shares (69,827 units at $0.25), decreasing direct ownership by 38% to 115,284 units (SEC Form 4)
  • INSIDER10h
    SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie sold $89,184 worth of shares (345,942 units at $0.26), decreasing direct ownership by 51% to 332,769 units (SEC Form 4)
  • INSIDER20d
    SEC Form 4 filed by Macrae Sandy
  • INSIDER20d
    SEC Form 4 filed by Dubois-Stringfellow Nathalie
  • INSIDER20d
    SEC Form 4 filed by Jain Nikunj
  • INSIDER20d
    SEC Form 4 filed by Davis Gregory D
  • INSIDER20d
    SEC Form 4 filed by Willoughby Scott B.
  • SEC24d
    SEC Form 10-K filed by Sangamo Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022